Dr Reddy's Q2 net profit falls as lower Lenalidomide sales drag revenue; beats estimates
Dr Reddy's Laboratories posted revenue of ₹8,671 crore for the September quarter, a 1.5% decline from a year earlier. Revenue rose 7% from the previous quarter. EBITDA fell 24.2% year-on-year. The EBITDA margin came in at 20.6%, beating estimates.